FierceBiotech

Metagenomi axes ALS program after seeing Biogen and Ionis flounder

Metagenomi is editing its pipeline, choosing to seek a partner for a program Moderna dropped and axing its amyotrophic lateral sclerosis (ALS) activities in response to setbacks at a competitor. The ...
Nasdaq

Voyager Provides Update on SOD1 ALS Gene Therapy Program

LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it has decided to ...
Nasdaq

Clene to Provide CNM-Au8® ALS Program Update

SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage ...
Seeking Alpha

Seelos Therapeutics Doses the First Amyotrophic Lateral Sclerosis (ALS) Patient with SLS-005 in an Expanded Access Program

- The Expanded Access Program is funded by a grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Accelerating Access to Critical Therapies for ALS (ACT for ALS) ...
Seeking Alpha

Voyager Provides Update on SOD1 ALS Gene Therapy Program

- All other programs remain on track; IND filings expected in 2025 for GBA1 and FA programs - LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (VYGR), a biotechnology ...